Gene

PPP2R2A

protein phosphatase 2 regulatory subunit Balpha

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PPP2R2A LOSS1
PARP Inhibitor ABT-888	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID12412 HeLa cell lines and A549 xenografts expression shRNA targeting PPP2R2A are sensitive to PARP inhibition by ABT-888 when PPP2R2A is knocked down. PMID 23087057 · Kalev et al., 2012 · Open in CIViC	civic
PPP2R2A Mutation1
Olaparib	Castration-Resistant Prostate Carcinoma	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID11206 This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n…

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved3 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Prostate Adenocarcinoma TCGA-PRAD	Prostate Adenocarcinoma	Ssm

Literature

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
· N Engl J Med · 2020 · PMID 32343890 · validated civic_curation pubmed